Device Trial Radar · NCT01597063
Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies
Last checked: Nov 19, 2026Latest source record: Apr 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,333
Actual
Start
Jul 2012
Primary completion
Feb 2014
Study completion Dec 2015
Sponsor
- Lead sponsor
- Sequenom, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 11, 2012
Design
- Study type
- Observational
- Who can join
- Female only, from 18 years, up to 34 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pregnant women with low risk indicators for fetal chromosomal aneuploidy will be enrolled. Study blood will be collected in the first or second trimester at a scheduled prenatal screening visit, processed to plasma, and stored frozen until analysis. Each pregnancy will be followed until delivery and the birth outcome recorded.
Conditions
- Aneuploidy
- Down Syndrome
- Noninvasive Prenatal Screening
Interventions
SEQureDx Trisomy TestDevice
Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate the false positive rate of SEQureDx Trisomy 21 TestTime frame: pregnancy outcome
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
University of South Alabama
Mobile, Alabama
New Horizon Women's Care
Chandler, Arizona
Precision Trials
Phoenix, Arizona
24 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.